About AxoGen (NASDAQ:AXGN)
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800
Debt
Debt-to-Equity Ratio0.79%
Current Ratio4.07%
Quick Ratio3.53%
Price-To-Earnings
Trailing P/E Ratio-129.84
Forward P/E Ratio-134.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$60.43 million
Price / Sales23.02
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book54.39
Profitability
EPS (Most Recent Fiscal Year)($0.31)
Net Income$-10,440,000.00
Net Margins-17.29%
Return on Equity-70.63%
Return on Assets-22.33%
Miscellaneous
Employees199
Outstanding Shares34,560,000
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) released its quarterly earnings data on Wednesday, February, 28th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. The medical equipment provider had revenue of $16.97 million for the quarter, compared to analyst estimates of $16.38 million. AxoGen had a negative return on equity of 70.63% and a negative net margin of 17.29%. The firm's revenue for the quarter was up 48.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.10) EPS. View AxoGen's Earnings History.
What price target have analysts set for AXGN?
8 brokerages have issued twelve-month price objectives for AxoGen's stock. Their forecasts range from $21.00 to $45.00. On average, they expect AxoGen's share price to reach $33.1429 in the next year. View Analyst Ratings for AxoGen.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include CONMED (CNMD), NxStage (NXTM), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Zynex (ZYXI), Biolife Solutions (BLFS), Viveve Medical (VIVE), Second Sight Medical (EYES), Edap Tms (EDAP), IRIDEX (IRIX), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Digirad (DRAD) and Aradigm (ARDM).
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Pres, CEO & Director (Age 56)
- Mr. Peter J. Mariani, CFO & Principal Accounting Officer (Age 54)
- Mr. Gregory G. Freitag, Gen. Counsel, Sr. VP of Bus. Devel. & Director (Age 56)
- Mr. Shawn F. McCarrey, Sr. VP of Sales (Age 60)
- Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)
Has AxoGen been receiving favorable news coverage?
Media stories about AXGN stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AxoGen earned a news impact score of 0.03 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 45.42 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $40.25.
How big of a company is AxoGen?
AxoGen has a market capitalization of $1.37 billion and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen employs 199 workers across the globe.
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
AxoGen (NASDAQ:AXGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for AxoGen in the last 12 months. Their average twelve-month price target is $33.1429, suggesting that the stock has a possible downside of 17.66%. The high price target for AXGN is $45.00 and the low price target for AXGN is $21.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $33.1429 | $33.1429 | $29.3333 | $17.40 |
| Price Target Upside: | 17.66% downside | 11.97% downside | 5.53% downside | 10.08% downside |
AxoGen (NASDAQ:AXGN) Consensus Price Target History
AxoGen (NASDAQ:AXGN) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
AxoGen (NASDAQ:AXGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AxoGen (NASDAQ AXGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.86%
Institutional Ownership Percentage: 67.78%
AxoGen (NASDAQ AXGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/20/2018 | Jamie Mark Grooms | Director | Sell | 63,395 | $27.67 | $1,754,139.65 | 5,827 |  |
| 2/15/2018 | Jamie Mark Grooms | CFO | Sell | 95,712 | $26.84 | $2,568,910.08 | | |
| 2/13/2018 | Jamie Mark Grooms | CFO | Sell | 10,300 | $26.21 | $269,963.00 | | |
| 12/12/2017 | Jamie Mark Grooms | Director | Sell | 38,405 | $26.35 | $1,011,971.75 | | |
| 12/8/2017 | Jamie Mark Grooms | Director | Sell | 84,295 | $26.38 | $2,223,702.10 | | |
| 12/6/2017 | Jamie Mark Grooms | Director | Sell | 21,290 | $26.22 | $558,223.80 | | |
| 11/20/2017 | Guido J Neels | Director | Sell | 1,150,000 | $19.74 | $22,701,000.00 | | |
| 9/11/2017 | Robert James Rudelius | Director | Sell | 16,143 | $18.00 | $290,574.00 | 43,273 | |
| 10/7/2016 | Amy Mcbride Wendell | Director | Buy | 13,333 | $7.50 | $99,997.50 | 13,333 | |
| 10/7/2016 | John P Engels | VP | Buy | 4,000 | $7.50 | $30,000.00 | 98,425 | |
| 10/7/2016 | Karen L Zaderej | CEO | Buy | 10,000 | $7.50 | $75,000.00 | 242,147 | |
| 10/7/2016 | Peter J Mariani | CFO | Buy | 3,333 | $7.50 | $24,997.50 | 3,333 | |
| 8/9/2016 | Joseph M Mandato | Director | Sell | 149,618 | $8.54 | $1,277,737.72 | | |
| 8/8/2016 | Joseph M Mandato | Director | Sell | 107,450 | $8.63 | $927,293.50 | | |
| 7/21/2016 | James E Flynn | Insider | Sell | 102,136 | $6.70 | $684,311.20 | | |
| 7/18/2016 | James E Flynn | Insider | Sell | 279,303 | $7.53 | $2,103,151.59 | | |
| 9/18/2015 | James E Flynn | Insider | Sell | 345,000 | $5.50 | $1,897,500.00 | | |
| 6/3/2015 | Joseph M Mandato | Director | Buy | 6,500 | $3.10 | $20,150.00 | | |
| 6/2/2015 | Lee Robert Johnston Jr | Insider | Buy | 5,000 | $3.06 | $15,300.00 | | |
| 4/8/2015 | James E Flynn | Insider | Sell | 144,385 | $3.25 | $469,251.25 | | |
| 12/10/2014 | Lee Robert Johnston Jr | CFO | Buy | 10,000 | $3.06 | $30,600.00 | | |
| 8/12/2014 | Mark Stephen Gold | Director | Buy | 20,000 | $2.29 | $45,800.00 | | |
| 8/8/2014 | Mark Stephen Gold | Director | Buy | 11,000 | $2.31 | $25,410.00 | | |
| 6/6/2014 | Lee Robert Johnston Jr | CFO | Buy | 10,000 | $2.58 | $25,800.00 | | |
| 6/3/2014 | Gregory Gene Freitag | CFO | Buy | 5,200 | $2.45 | $12,740.00 | | |
| 6/3/2014 | Karen L Zaderej | CEO | Buy | 5,000 | $2.43 | $12,150.00 | | |
| 5/20/2014 | Jill F Schiaparelli | SVP | Buy | 2,000 | $2.63 | $5,260.00 | | |
| 5/12/2014 | Karen L Zaderej | CEO | Buy | 5,000 | $2.70 | $13,500.00 | | |
| 5/7/2014 | Mark Stephen Gold | Director | Buy | 1,977 | $2.60 | $5,140.20 | | |
| 3/13/2014 | Karen L Zaderej | CEO | Buy | 1,500 | $3.49 | $5,235.00 | | |
| 8/29/2013 | Shawn F Mccarrey | SVP | Buy | 25,000 | $3.21 | $80,250.00 | | |
| 8/24/2013 | Shawn F Mccarrey | SVP | Buy | 5,000 | $3.00 | $15,000.00 | | |
| 8/14/2013 | Jill F Schiaparelli | SVP | Buy | 5,000 | $3.00 | $15,000.00 | | |
| 8/14/2013 | John Frederick Harper | Director | Buy | 66,666 | $3.00 | $199,998.00 | | |
| 8/14/2013 | Karen L Zaderej | CEO | Buy | 8,334 | $3.00 | $25,002.00 | | |
| 12/4/2012 | Jill F Schiaparelli | SVP | Buy | 2,000 | $2.55 | $5,100.00 | | |
| 11/29/2012 | Jill F Schiaparelli | SVP | Buy | 1,000 | $2.70 | $2,700.00 | | |
| 11/15/2012 | Jill F Schiaparelli | SVP | Buy | 2,750 | $2.56 | $7,040.00 | | |
| 10/1/2012 | John Frederick Harper | Director | Buy | 86,557 | $3.61 | $312,470.77 | | |
(Data available from 1/1/2013 forward)
AxoGen (NASDAQ AXGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
finance.yahoo.com - April 18 at 9:29 AM |
 | AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
feeds.benzinga.com - April 18 at 7:52 AM |
 | Zacks: Brokerages Expect AxoGen, Inc (AXGN) Will Post Quarterly Sales of $17.21 Million
www.americanbankingnews.com - April 18 at 3:58 AM |
| AxoGen, Inc (AXGN) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM |
| AxoGen (AXGN) Receives New Coverage from Analysts at Leerink Swann
www.americanbankingnews.com - April 15 at 9:45 AM |
| AxoGen (AXGN) Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 13 at 4:55 PM |
 | AxoGen Offers An Exciting Story At Nosebleed Prices
seekingalpha.com - April 12 at 4:26 PM |
 | AxoGen, Inc. Announces 2018 Annual Shareholders' Meeting
globenewswire.com - April 12 at 10:21 AM |
| AxoGen (AXGN) and Sonova (SONVY) Financial Comparison
www.americanbankingnews.com - April 10 at 11:31 PM |
| Comparing AxoGen (AXGN) and Its Competitors
www.americanbankingnews.com - April 10 at 9:15 AM |
| Head-To-Head Comparison: AxoGen (AXGN) vs. Its Rivals
www.americanbankingnews.com - April 9 at 11:18 PM |
| Analyzing AxoGen (AXGN) and The Competition
www.americanbankingnews.com - April 6 at 5:13 PM |
| AxoGen (AXGN) and Its Rivals Financial Survey
www.americanbankingnews.com - April 4 at 11:47 AM |
| AxoGen (AXGN) Price Target Raised to $26.00 at Leerink Swann
www.americanbankingnews.com - April 1 at 10:52 PM |
| AxoGen, Inc. (AXGN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 8:03 AM |
| Zacks: Analysts Anticipate AxoGen, Inc. (AXGN) Will Announce Quarterly Sales of $17.21 Million
www.americanbankingnews.com - April 1 at 4:02 AM |
| Brokerages Expect AxoGen, Inc. (AXGN) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:28 AM |
| AxoGen (AXGN) Downgraded by BidaskClub
www.americanbankingnews.com - March 28 at 9:49 PM |
 | AxoGen (AXGN) Enters Overbought Territory March 27, 2018
www.zacks.com - March 27 at 4:23 PM |
| AxoGen (AXGN) Enters Overbought Territory
finance.yahoo.com - March 27 at 4:23 PM |
| Jefferies Group Increases AxoGen (AXGN) Price Target to $45.00
www.americanbankingnews.com - March 19 at 11:11 AM |
| Zacks: Brokerages Expect AxoGen, Inc. (AXGN) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - March 13 at 12:03 PM |
| Brokers Issue Forecasts for AxoGen, Inc.'s FY2018 Earnings (AXGN)
www.americanbankingnews.com - March 7 at 11:48 AM |
| AxoGen, Inc. (AXGN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 7 at 11:45 AM |
| Blog Exposure - Boston Scientific Acquired EMcision for Undisclosed Amount
finance.yahoo.com - March 7 at 9:36 AM |
| AWM Investment Company Inc. Has $7.97 Million Holdings in AxoGen, Inc. (AXGN)
www.americanbankingnews.com - March 6 at 4:44 AM |
| Are Earnings Prospects Improving For Loss-Making AxoGen Inc’s (NASDAQ:AXGN)?
finance.yahoo.com - March 5 at 5:00 PM |
| AxoGen, Inc. (AXGN) Position Lowered by Millrace Asset Group Inc.
www.americanbankingnews.com - March 5 at 12:54 PM |
| Q3 2018 Earnings Estimate for AxoGen, Inc. Issued By William Blair (AXGN)
www.americanbankingnews.com - March 5 at 4:30 AM |
| Q1 2018 EPS Estimates for AxoGen, Inc. Reduced by Leerink Swann (AXGN)
www.americanbankingnews.com - March 5 at 2:56 AM |
| Jefferies Group Comments on AxoGen, Inc.'s Q1 2018 Earnings (AXGN)
www.americanbankingnews.com - March 5 at 2:56 AM |
| Contrasting Zynex (ZYXI) & AxoGen (AXGN)
www.americanbankingnews.com - March 4 at 12:02 PM |
 | AxoGen Inc. (AXGN) Has Broken Out To A New High On Q4 Results - Nasdaq
www.nasdaq.com - March 3 at 5:09 PM |
 | AxoGen (AXGN) Q4 2017 Earnings Conference Call Transcript - Motley Fool
www.fool.com - March 3 at 5:09 PM |
| AxoGen (AXGN) PT Set at $38.00 by Lake Street Capital
www.americanbankingnews.com - March 2 at 7:48 PM |
| AxoGen, Inc. (AXGN) is Next Century Growth Investors LLC's 5th Largest Position
www.americanbankingnews.com - March 2 at 5:58 PM |
| Brokers Offer Predictions for AxoGen, Inc.'s FY2020 Earnings (AXGN)
www.americanbankingnews.com - March 2 at 5:10 PM |
| AxoGen (AXGN) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 2 at 5:05 PM |
| AxoGen (AXGN) PT Raised to $34.00 at JMP Securities
www.americanbankingnews.com - March 1 at 7:07 PM |
| AxoGen, Inc. (AXGN) Shares Sold by Essex Woodlands Management Inc.
www.americanbankingnews.com - March 1 at 2:12 PM |
| AxoGen (AXGN) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 28 at 9:20 PM |
 | BRIEF-Axogen Inc Q4 Adjusted Loss Per Share $0.07
www.reuters.com - February 28 at 4:59 PM |
| AxoGen, Inc. to Host Earnings Call
finance.yahoo.com - February 28 at 4:59 PM |
| AxoGen, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - February 28 at 4:59 PM |
| EAM Investors LLC Sells 73,412 Shares of AxoGen, Inc. (AXGN)
www.americanbankingnews.com - February 27 at 3:00 PM |
| AxoGen, Inc. (AXGN) Position Cut by Cortina Asset Management LLC
www.americanbankingnews.com - February 27 at 1:40 PM |
| AxoGen, Inc. to Present at 30th Annual ROTH Conference
finance.yahoo.com - February 27 at 9:30 AM |
| AxoGen Named Employee Engagement Best Practices Award Winner by DecisionWise International
finance.yahoo.com - February 27 at 9:30 AM |
| Zacks: Analysts Anticipate AxoGen, Inc. (AXGN) Will Announce Quarterly Sales of $16.09 Million
www.americanbankingnews.com - February 26 at 4:38 AM |
| BidaskClub Upgrades AxoGen (AXGN) to "Strong-Buy"
www.americanbankingnews.com - February 25 at 12:00 AM |
AxoGen (NASDAQ:AXGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AxoGen (NASDAQ:AXGN) Income Statement, Balance Sheet and Cash Flow Statement
AxoGen (NASDAQ AXGN) Stock Chart for Thursday, April, 19, 2018
Loading chart…
